Skip to main navigation

Top Navigation

Home
About Us
Technology
Pipeline
Partnerships
Investors
Careers
Contact
- Overview
- Patient Enquiries

Select Page

Annual Reports and AGM

Toolkit

Subscribe
RSS Feeds
Contact IR
Presentations

Sub Nav News & Filings

Annual Reports and AGM

Quarterly Results

Annual Reports and AGM

Show all

Annual Reports

2023/2024

Form 10-K
Annual Report and Accounts for the Year Ended 31 December 2023 4.2 MB
Form of UK proxy card 2024 143.1 KB
Notice of Barinthus Biotherapeutics plc Annual General Meeting 2024 138 KB
Proxy Statement 936.2 KB
Poll Voting Results of the 2024 AGM 83.3 KB

Annual Reports

2022/2023

Form 10-K
Proxy statement May 2023 4.3 MB
Annual Report and Accounts for the Year Ended 31 December 2022 3.8 MB
Notice of Vaccitech plc Annual General Meeting May 2023 653.6 KB
Form of UK Proxy Card May 2023 606.3 KB
Poll Voting Results of the May 2023 AGM 193.9 KB
Form of UK Proxy Card - General Meeting, November 41.9 KB
Proxy Statement - General Meeting, November 371.4 KB
UK General Meeting Notice, November 179.8 KB

Annual Reports

2021/2022

Form 10-K
Proxy statement 2.5 MB
Annual Report and Accounts for the Year Ended 31 December 2021 4.1 MB
Notice of Vaccitech plc Annual General Meeting 2022 410.4 KB
Form of UK Proxy Card 2022 510.2 KB

Barinthus Biotherapeutics plc

Unit 6-10
Zeus Building
Rutherford Avenue
Harwell OX11 0DF
United Kingdom

T: +44 (0)1865 818808

Footer Links

Home
About
Sitemap
Privacy Policy
Privacy Notice
Careers
Contact

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company focused on the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer.

© Barinthus Biotherapeutics 2024 All rights reserved.

Social Media Links

Follow us on X
Follow us on LinkedIn